Literature DB >> 20685934

Construction and immunogenicity of recombinant adenovirus vaccines expressing the HMW1, HMW2, or Hia adhesion protein of nontypeable Haemophilus influenzae.

Linda E Winter1, Stephen J Barenkamp.   

Abstract

The objective of the present study was to construct and assess the immunogenicity of recombinant adenovirus vectors expressing the HMW1, HMW2, or Hia protein of nontypeable Haemophilus influenzae (NTHi). These proteins are critical adhesins and potential protective antigens expressed by NTHi. Segments of the hmw1A and hmw2A structural genes that encode the distal one-half of mature HMW1 or HMW2 were cloned into the T7 expression vector pGEMEX-2. These constructs encoded stable HMW1 or HMW2 recombinant fusion protein that expresses B-cell epitopes common to most NTHi strains. A segment of the hia gene that encodes the surface-exposed portion of mature Hia was also cloned into pGEMEX-2. The resulting T7 gene 10 translational fusions were excised from the parent plasmids and cloned into the shuttle plasmid pDC316. Cotransfection of HEK 293 cells with the pDC316 derivatives and pBHGloxΔE1,3Cre resulted in the production of viral plaques from which recombinant adenoviruses expressing fusion proteins were recovered. Chinchillas immunized intraperitoneally with a single 10(8)-PFU dose of either the HMW2 or Hia adenoviral construct developed high anti-HMW2 or anti-Hia serum antibody titers within 4 weeks of immunization. Chinchillas immunized intranasally with a single 10(7)- to 10(9)-PFU dose of the Hia adenoviral construct also developed high anti-Hia serum antibody titers within 8 weeks of immunization. Recombinant adenoviruses represent a promising system to induce mucosal and systemic immunity and protection against mucosal diseases such as otitis media. Recombinant adenoviruses expressing recombinant HMW1, HMW2, or Hia protein will be important new tools in NTHi vaccine development efforts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685934      PMCID: PMC2952983          DOI: 10.1128/CVI.00115-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  63 in total

1.  Identification of a 16,600-dalton outer membrane protein on nontypeable Haemophilus influenzae as a target for human serum bactericidal antibody.

Authors:  T F Murphy; L C Bartos; P A Rice; M B Nelson; K C Dudas; M A Apicella
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Human bactericidal antibody response to outer membrane protein P2 of nontypeable Haemophilus influenzae.

Authors:  T F Murphy; L C Bartos
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

3.  Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children.

Authors:  Lolita Piglansky; Eugene Leibovitz; Simon Raiz; David Greenberg; Joseph Press; Alberto Leiberman; Ron Dagan
Journal:  Pediatr Infect Dis J       Date:  2003-05       Impact factor: 2.129

4.  Anatomy of the nasal cavity in the chinchilla.

Authors:  Joseph A Jurcisek; Joan E Durbin; Donna F Kusewitt; Lauren O Bakaletz
Journal:  Cells Tissues Organs       Date:  2003       Impact factor: 2.481

5.  Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway.

Authors:  Nicola J Philpott; Marcelo Nociari; Keith B Elkon; Erik Falck-Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

6.  Human antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae mediate opsonophagocytic activity.

Authors:  Linda E Winter; Stephen J Barenkamp
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 7.  Mucosal immunization against respiratory bacterial pathogens.

Authors:  A Ruth Foxwell; Jennelle M Kyd; Allan W Cripps
Journal:  Expert Rev Vaccines       Date:  2003-08       Impact factor: 5.217

8.  Changes in frequency and pathogens causing acute otitis media in 1995-2003.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2004-09       Impact factor: 2.129

9.  Structural basis for host recognition by the Haemophilus influenzae Hia autotransporter.

Authors:  Hye-Jeong Yeo; Shane E Cotter; Sven Laarmann; Twyla Juehne; Joseph W St Geme; Gabriel Waksman
Journal:  EMBO J       Date:  2004-03-18       Impact factor: 11.598

Review 10.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

View more
  5 in total

1.  Selection and Counterselection of Hia Expression Reveals a Key Role for Phase-Variable Expression of Hia in Infection Caused by Nontypeable Haemophilus influenzae.

Authors:  John M Atack; Linda E Winter; Joseph A Jurcisek; Lauren O Bakaletz; Stephen J Barenkamp; Michael P Jennings
Journal:  J Infect Dis       Date:  2015-02-23       Impact factor: 5.226

2.  Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt.

Authors:  Gang Deng; Xiang-Jun Huang; Hong-Wu Luo; Fei-Zhou Huang; Xun-Yang Liu; Yong-Heng Wang
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

Review 3.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

4.  Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure.

Authors:  Matteo De Chiara; Derek Hood; Alessandro Muzzi; Derek J Pickard; Tim Perkins; Mariagrazia Pizza; Gordon Dougan; Rino Rappuoli; E Richard Moxon; Marco Soriani; Claudio Donati
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-25       Impact factor: 11.205

5.  The use of adenoviral vectors in gene therapy and vaccine approaches.

Authors:  Natália Meneses Araújo; Ileana Gabriela Sanchez Rubio; Nicholas Pietro Agulha Toneto; Mirian Galliote Morale; Rodrigo Esaki Tamura
Journal:  Genet Mol Biol       Date:  2022-10-07       Impact factor: 2.087

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.